1. previous vaccination with investigational or registered non-mrna vaccines against covid-19. 2. history of presence of pulmonary disorders (chronic obstructive pulmonary lung disease etc) or asthma (exception of allergic asthma, which is allowed). 3. history or presence of thrombocytopenia and/or bleeding disorders. 4. a positive serum pregnancy test at screening or urine pregnancy test prior to study injection, women who are planning to become pregnant during the study, or women who are breastfeeding. 5. clinically relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine, inflammatory, autoimmune, central nervous system or neurological diseases. 6. use of immunosuppressive drugs as e.g. corticosteroids (excluding topical preparations and inhalers) within 3 months prior to vaccination or 6 months for chemotherapies and all along the study. 7. vaccination within 2 weeks prior to vaccination or planning to receive a licensed vaccine before month 3 (e.g. inactivated influenza vaccine). 8. history of severe adverse reactions to vaccine administration, including anaphylaxis and related symptoms, such as urticaria, respiratory difficulty, angioedema and abdominal pain to vaccines, or history of known or suspected allergic reaction likely to be exacerbated by any component of the investigational vaccine. 9. participation in another investigational clinical study within four weeks before the screening visit or planned before the study completion. 10. subjects with confirmed or suspected immunodeficiency. 11. sars-cov-2 infection within the past 2 weeks3 months prior to enrolment, or ongoing symptom of covid-19. 12. any condition that in the opinion of the principal investigator (pi) would jeopardize the safety or rights of a person participating in the trial or would render the person unable to comply with the protocol.

1. previous vaccination with investigational or registered non-mrna vaccines against covid-19. 2. history of presence of pulmonary disorders (chronic obstructive pulmonary lung disease etc) or asthma (exception of allergic asthma, which is allowed). 3. history or presence of thrombocytopenia and/or bleeding disorders. 4. a positive serum pregnancy test at screening or urine pregnancy test prior to study injection, women who are planning to become pregnant during the study, or women who are breastfeeding. 5. clinically relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine, inflammatory, autoimmune, central nervous system or neurological diseases. 6. use of immunosuppressive drugs as e.g. corticosteroids (excluding topical preparations and inhalers) within 3 months prior to vaccination or 6 months for chemotherapies and all along the study. 7. vaccination within 2 weeks prior to vaccination or planning to receive a licensed vaccine before month 3 (e.g. inactivated influenza vaccine). 8. history of severe adverse reactions to vaccine administration, including anaphylaxis and related symptoms, such as urticaria, respiratory difficulty, angioedema and abdominal pain to vaccines, or history of known or suspected allergic reaction likely to be exacerbated by any component of the investigational vaccine. 9. participation in another investigational clinical study within four weeks before the screening visit or planned before the study completion. 10. subjects with confirmed or suspected immunodeficiency. 11. sars-cov-2 infection within the past 2 weeks3 months prior to enrolment, or ongoing symptom of covid-19. 12. any condition that in the opinion of the principal investigator (pi) would jeopardize the safety or rights of a person participating in the trial or would render the person unable to comply with the protocol.

previous vaccination with investigational or registered non-mrna vaccines against covid-19. history of presence of pulmonary disorders (chronic obstructive pulmonary lung disease etc) or asthma (exception of allergic asthma, which is allowed). history or presence of thrombocytopenia and/or bleeding disorders. a positive serum pregnancy test at screening or urine pregnancy test prior to study injection, women who are planning to become pregnant during the study, or women who are breastfeeding. clinically relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine, inflammatory, autoimmune, central nervous system or neurological diseases. use of immunosuppressive drugs as e.g. corticosteroids (excluding topical preparations and inhalers) within 3 months prior to vaccination or 6 months for chemotherapies and all along the study. vaccination within 2 weeks prior to vaccination or planning to receive a licensed vaccine before month 3 (e.g. inactivated influenza vaccine). history of severe adverse reactions to vaccine administration, including anaphylaxis and related symptoms, such as urticaria, respiratory difficulty, angioedema and abdominal pain to vaccines, or history of known or suspected allergic reaction likely to be exacerbated by any component of the investigational vaccine. participation in another investigational clinical study within four weeks before the screening visit or planned before the study completion. subjects with confirmed or suspected immunodeficiency. sars-cov-2 infection within the past 2 weeks3 months prior to enrolment, or ongoing symptom of covid-19. any condition that in the opinion of the principal investigator (pi) would jeopardize the safety or rights of a person participating in the trial or would render the person unable to comply with the protocol.

previous vaccination with investigational or registered non-mrna vaccines against covid-19. history of presence of pulmonary disorders (chronic obstructive pulmonary lung disease etc) or asthma (exception of allergic asthma, which is allowed). history or presence of thrombocytopenia and/or bleeding disorders. a positive serum pregnancy test at screening or urine pregnancy test prior to study injection, women who are planning to become pregnant during the study, or women who are breastfeeding. clinically relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine, inflammatory, autoimmune, central nervous system or neurological diseases. use of immunosuppressive drugs as e.g. corticosteroids (excluding topical preparations and inhalers) within 3 months prior to vaccination or 6 months for chemotherapies and all along the study. vaccination within 2 weeks prior to vaccination or planning to receive a licensed vaccine before month 3 (e.g. inactivated influenza vaccine). history of severe adverse reactions to vaccine administration, including anaphylaxis and related symptoms, such as urticaria, respiratory difficulty, angioedema and abdominal pain to vaccines, or history of known or suspected allergic reaction likely to be exacerbated by any component of the investigational vaccine. participation in another investigational clinical study within four weeks before the screening visit or planned before the study completion. subjects with confirmed or suspected immunodeficiency. sars-cov-2 infection within the past 2 weeks3 months prior to enrolment, or ongoing symptom of covid-19. any condition that in the opinion of the principal investigator (pi) would jeopardize the safety or rights of a person participating in the trial or would render the person unable to comply with the protocol.